Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 64, Issue 3, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01538-19
Keywords
Aotus monkeys; JPC-3210; Plasmodium falciparum; Plasmodium vivax; antimalarial drug discovery; in vitro drug susceptibility; pharmacokinetics
Categories
Funding
- Australian Defence Organisation
- Jacobus Pharmaceutical Company, Inc
- USAMRMC (US Army Medical Research and Materiel Command) Grant [W81XWH-07-044]
Ask authors/readers for more resources
Nonimmune Aotus monkeys infected with Plasmodium falciparum and Plasmodium vivax were cured of their infections when treated with a single oral dose of 5 mg/kg and 10 mg/kg of the 2-aminomethylphenol, JPC-3210, respectively. Corresponding mean blood elimination half-lives of JPC-3210 were lengthy at 19.1 days and 20.5 days, respectively. This in vivo potency and lengthy half-life supports the further development of JPC-3210 as a promising, long-acting blood schizontocidal antimalarial for malaria treatment and prevention.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
